Pacific Biosciences vs Florence Healthcare

Side-by-side comparison of AI visibility scores, market position, and capabilities

Florence Healthcare leads in AI visibility (74 vs 53)
Pacific Biosciences logo

Pacific Biosciences

GrowthLife Sciences & BioTech

Long-Read Sequencing

Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 revenue with 40%+ gross margins.

AI VisibilityBeta
Overall Score
C53
Category Rank
#56 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
56
Gemini
48

About

Pacific Biosciences (PacBio) was founded in 2004 in Menlo Park, California and pioneered single-molecule real-time (SMRT) sequencing technology, enabling long-read DNA sequencing that can span tens of thousands of base pairs per read. This capability is essential for resolving complex genomic regions—structural variants, repeat expansions, methylation patterns, and full-length transcripts—that short-read platforms like Illumina cannot accurately assemble.\n\nPacBio's Revio system, launched in 2023, offers a dramatic improvement in throughput and cost efficiency over prior instruments, targeting both research and clinical sequencing laboratories. Key applications include rare disease diagnosis, pharmacogenomics, plant and animal genomics, and clinical oncology. The company guides to $150–$170 million in FY2025 revenue with gross margins exceeding 40% and a path to cash flow breakeven by 2027.\n\nPacBio competes primarily with Oxford Nanopore Technologies in the long-read segment, together driving adoption of long-read sequencing for comprehensive genome assembly and clinical applications. The company is expanding its high-accuracy (HiFi) chemistry and developing Onso, a short-read system, to capture a broader share of the sequencing market. With approximately $260 million in cash, PacBio is well-positioned to scale its clinical business.

Full profile
Florence Healthcare logo

Florence Healthcare

LeaderLife Sciences & BioTech

Clinical Trial Site Enablement Platform

Florence Healthcare is the leading clinical trial site enablement platform, connecting 12,000+ research sites in 45 countries; $116M raised from Insight Partners; processes 6.5M+ research workflows monthly via remote digital document management.

AI VisibilityBeta
Overall Score
B74
Category Rank
#6 of 198
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
71
Gemini
79

About

Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to streamline regulatory documentation, remote monitoring, and operational workflows. Founded in Atlanta and backed by Insight Partners, Florence has built the industry's largest connected network of clinical trial sites — over 12,000 sites across 45 countries — making it the infrastructure backbone for decentralized and hybrid clinical research.

Full profile

AI Visibility Head-to-Head

53
Overall Score
74
#56
Category Rank
#6
79
AI Consensus
75
stable
Trend
stable
54
ChatGPT
80
56
Perplexity
71
48
Gemini
79
51
Claude
74
49
Grok
72

Key Details

Category
Long-Read Sequencing
Clinical Trial Site Enablement Platform
Tier
Growth
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Pacific Biosciences
Long-Read Sequencing

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.